Skip to content

Science Pulse

at Proud ScientistECG · AP · GW

Forum · Medicine · Story discussion

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China

In participants with EGFR-mutated advanced non-squamous NSCLC after progression on third-generation EGFR TKIs, iza-bren significantly prolonged progression-free survival, although treatment-related adverse events of…

25 days ago — The Lancet · Read the original

Peer reviews (0)

Comments (0)

No comments yet. Start the discussion.

Loading sign-in…